U.S. markets closed

Dimerix Limited (DXB.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.1550-0.0150 (-8.82%)
At close: 03:00PM AEST

Dimerix Limited

425 Smith Street
Fitzroy, VIC 3065
61 3 0081 3321

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D.CEO, MD & Director373.45kN/AN/A
Mr. Hamish George B.Com., C.A.CFO & Company Sec.N/AN/AN/A
Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.Chief Scientific AdvisorN/AN/AN/A
Dr. Ashish Soman M.B.A., M.D., MBBSChief Medical OfficerN/AN/AN/A
Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB.Bus. Devel. OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 and is headquartered in Fitzroy, Australia.

Corporate Governance

Dimerix Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.